---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-173983"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:34:33.883467+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian reports cash of $563.4M; BLA for veligrotug on track for 2H 2025

## Summary
- Cash, cash equivalents and short-term investments $563.4M as of June 30, 2025, down from $636.6M at March 31, 2025; runway into 2H 2027.
- R&D expenses $86.6M in Q2 2025 (up from $56.2M in Q2 2024) driven by more clinical trials and higher headcount.
- Veligrotug BLA submission on track for 2H 2025; U.S. commercial launch anticipated in 2026 if approved.
- Exclusive license with Kissei for Japan: $70M upfront, up to $315M in milestones, plus tiered royalties.
- Veligrotug durability data: 70% of proptosis responders at week 15 maintained response at week 52.

## SEC filing metadata
- accession: 0001193125-25-173983
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/0001193125-25-173983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-173983
- JSON: https://secwatch.observer/filing/0001193125-25-173983.json
- Plain text: https://secwatch.observer/filing/0001193125-25-173983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.